PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsAprepitant
Emend(aprepitant)
Aponvie, Aprepitant, Cinvanti, Emend (aprepitant) is a small molecule pharmaceutical. Aprepitant was first approved as Emend on 2003-03-26. It has been approved in Europe to treat neoplasms, postoperative nausea and vomiting, and vomiting. The pharmaceutical is active against substance-P receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Aponvie, Aprepitant, Cinvanti, Emend (discontinued: Aprepitant, Emend)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Aprepitant
Tradename
Company
Number
Date
Products
APREPITANTAzurityN-218754 RX2026-06-16
1 products, RLD, RS
APONVIEHeron TherapeuticsN-216457 RX2022-09-16
1 products, RLD, RS
CINVANTIHeron TherapeuticsN-209296 RX2017-11-09
1 products, RLD, RS
EMENDMerck & CoN-021549 RX2003-03-26
2 products, RLD, RS
EMENDMerck & CoN-207865 RX2015-12-17
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
aponvieNew Drug Application2026-04-01
aprepitantANDA2026-03-27
aprepitant aprepitantANDA2026-06-11
cinvantiNew Drug Application2026-04-01
emendNew Drug Application2026-02-20
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Aprepitant, Aponvie, Heron Theraps Inc
95612292035-09-18DPU-2161, U-3440
98084652035-09-18U-2161, U-3440
99747422035-09-18DP
99747932035-09-18DP
99747942035-09-18DPU-2161, U-3440
105002082035-09-18DP
106248502035-09-18U-2161, U-3440
109530182035-09-18U-2161, U-3440
111731182035-09-18DP
Aprepitant, Emend, Merck
82581322027-09-26DPU-901, U-1743, U-1916
ATC Codes
A: Alimentary tract and metabolism drugs
— A04: Antiemetics and antinauseants
— A04A: Antiemetics and antinauseants
— A04AD: Other antiemetics in atc
— A04AD12: Aprepitant
HCPCS
Code
Description
J0185
Injection, aprepitant, 1 mg
J1453
Injection, fosaprepitant, 1 mg
J8501
Aprepitant, oral, 5 mg
Clinical
Clinical Trials
225 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149—G89.1812———2
Covid-19D000086382—U07.1—1———1
AgnosiaD000377EFO_0007136F8811———1
BunionD000071378—M21.6111———1
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAprepitant
INNaprepitant
Description
Aprepitant is a morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. It has a role as an antidepressant, an antiemetic, a peripheral nervous system drug, a neurokinin-1 receptor antagonist and a substance P receptor antagonist. It is a member of triazoles, a member of morpholines, a cyclic acetal and a member of (trifluoromethyl)benzenes.
Classification
Small molecule
Drug classtachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Identifiers
PDB—
CAS-ID170729-80-3
RxCUI—
ChEMBL IDCHEMBL1471
ChEBI ID499361
PubChem CID135413536
DrugBankDB00673
UNII ID1NF15YR6UY (ChemIDplus, GSRS)
Target
Agency Approved
TACR1
TACR1
Organism
Homo sapiens
Gene name
TACR1
Gene synonyms
NK1R, TAC1R
NCBI Gene ID
6869
Protein name
substance-P receptor
Protein synonyms
neurokinin receptor 1, NK-1 receptor, NK-1R, Tachykinin receptor 1, tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor)
Uniprot ID
P25103
Mouse ortholog
Tacr1 (21336)
substance-P receptor (Q8BYR7)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Emend – Merck & Co
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Cinvanti – Heron Therapeutics /de/
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Aponvie – Heron Therapeutics /de/
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Aprepitant
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 7,301 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
10,340 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use